Gabaergic Striatal Interneurons In Huntington'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
GABAergic striatal interneurons play crucial roles in modulating the direct and indirect pathway medium spiny neurons (MSNs) that form the basal ganglia output. In Huntington's disease (HD), these interneurons exhibit differential vulnerability that contributes to motor and cognitive dysfunction.
The striatum contains several distinct GABAergic interneuron populations:
- Fast-spiking interneurons (FSIs): Most abundant GABAergic interneuron
- Total population: ~1-2% of striatal neurons
- Local connectivity: Form perisomatic synapses on MSNs
- Marker expression: Parvalbumin, calbindin
- Giant aspiny neurons: Largest striatal interneurons
- Type I cholinergic: Tonically active neurons (TANs)
- Neuromodulatory role: Acetylcholine release
- Medium-sized aspiny neurons: Dendritic targeting
- NPY co-expression: Neuropeptide Y
- Cortical input modulation: Integrate cortical afferents
- Least common: <1% of interneurons
- Local circuit role: Feedforward inhibition
- PV+ → MSN soma: Powerful somatic inhibition
- SST+ → MSN dendrites: Dendritic inhibition
- Cholinergic → MSNs: Nicotinic modulation
- Calretinin → unknown: Circuit modulation
Parvalbumin-positive interneurons show:
- Relative preservation: More resistant than MSNs
- Early dysfunction: Functional impairment before death
- Network effects: Disrupted feedforward inhibition
- Excitability changes: Altered firing patterns
TANs demonstrate:
- Progressive loss: 30-50% reduction in HD
- Dysfunction early: Abnormal responses in premanifest HD
- Dopamine interaction: Lost modulation in HD
- Cortical dysregulation: Impaired integration
Somatostatin neurons show:
- Vulnerability: Moderate loss in HD
- NPY reduction: Decreased peptide levels
- Dendritic dysfunction: Impaired dendritic integration
- Inflammation sensitivity: Vulnerable to neuroinflammation
- Cell-autonomous toxicity: Direct interneuron effects
- Transcriptional dysregulation: GABAergic gene changes
- Synaptic dysfunction: Altered inhibition
- Energy deficits: Mitochondrial impairment
- Inhibition/excitation imbalance: Too little or too much inhibition
- MSN disinhibition: Loss of precise control
- Oscillation disruption: Altered beta oscillations
- Movement abnormalities: Hyperkinetic features
- High firing rate: 100-200 Hz sustained
- Short spike duration: <0.3 ms
- Minimal adaptation: Non-adapting firing
- Strong inhibition: Powerful postsynaptic effects
- Burst-pause pattern: Response to rewards
- Slow firing: 5-10 Hz baseline
- DopaMine modulation: Lost in HD
- Cortical input: Responsive to sensory cues
- Low threshold firing: Depolarized resting
- Dendritic spikes: Calcium-dependent
- Late firing: After depolarization
- Adaptation: Frequency-dependent
- GABA agonists: Enhance surviving interneuron function
- Optogenetics: Restore PV+ activity
- Transplantation: GABAergic interneuron grafts
- Cholinergic agonists: M1/M4 targeting
- Acetylcholinesterase inhibitors: Increase ACh
- Nicotinic modulators: α4β2, α7 agonists
- SST agonists: Peptidergic modulation
- NPY modulation: Downstream effects
- Anti-inflammatory: Protect SST+ neurons
- Deep brain stimulation: Modulate striatal output
- Gene therapy: Restore interneuron function
- Cell replacement: Interneuron transplantation
- R6/2 mice: Early onset HD model
- Hdh knock-in: Full-length mutant huntingtin
- Conditional models: Cell-type specific effects
- Post-mortem tissue: Interneuron counts
- iPSC models: Patient-derived interneurons
- Imaging: PET cholinergic markers
- PET imaging: VMAT2, VAChT ligands
- CSF: Acetylcholine, GABA levels
- EEG: Oscillation changes
- Motor symptoms: Interneuron modulation
- Cognitive decline: Circuit restoration
- Psychiatric features: Dopamine balance
The study of Gabaergic Striatal Interneurons In Huntington'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Cicchetti F, Parent A. Striatal interneurons in Huntington's disease. Brain Res Rev. 2005;50(1):47-59.
- Raymond LA, Andre VM, Cepeda C, et al. Striatal neuronal dysfunction in Huntington disease. Exp Neurol. 2011;232(2):119-129.
- Holler S, Kosmowska M, Hacker S, et al. Striatal GABAergic interneuron dysfunction in the Q175 mouse model of Huntington's disease. Neurobiol Dis. 2021;158:105455.
- Tanimura A, Liu J, Surmeier DJ. Aberrant striatal neuronal function in Huntington's disease. Exp Neurol. 2018;301:120-129.
- Rebec GV. Dysregulation of corticostriatal connectivity in Huntington's disease: A role for dopamine modulation. Brain Res Bull. 2018;141:85-91.